)
)
)
Phanes Therapeutics
Phanes Therapeutics, Inc. is a clinical-stage biotech advancing three Phase I/II immuno-oncology programs: mavrostobart (PT199), a best-in-class monoclonal antibody against CD73 (MORNINGSTAR study); and two first-in-class bispecific antibodies, spevatamig (PT886) (TWINPEAK study) and peluntamig (PT217) (SKYBRIDGE study), both granted FDA Orphan Drug and Fast Track designations. The company’s pipeline is powered by its proprietary biologics platforms—PACbody®, SPECpair®, and ATACCbody®—which enable development of differentiated, manufacturable antibody therapeutics. Backed by deep scientific expertise, Phanes is poised to deliver transformative cancer therapies and strategic partnering opportunities.
For more information about Phanes Therapeutics, please visit www.phanesthera.com
Address
San DiegoCA
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)